. Author manuscript; available in PMC: 2017 Mar 1.

Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2015 Dec 18;16(3):152–162. doi: 10.1016/j.clml.2015.12.003

Table 7.

Long-term outcomes for patients treated with dasatinib or nilotinib by pre-existing organ function

4-yr survival, %	Dasatinib^* N=107			Nilotinib^* N=108			Overall N=215			P
4-yr survival, %	Normal N=89	Liver N=13	Renal N=6	Normal N=91	Liver N=9	Renal N=9	Normal N=180	Liver N=22	Renal N=15	Normal vs. Liver	Normal vs. Renal
FFS	76	73	55	81	52	67	78	63	62	0.832	0.206
TFS	97	90	100	93	100	100	94	93	100	0.806	0.730
EFS	90	91	100	92	83	88	91	88	93	0.976	0.426
OS	97	100	100	95	88	83	94	96	90	0.886	0.012

One patient in each cohort had both renal and liver dysfunction.

Abbreviations: FFS, failure free survival; TFS, treatment free survival; EFS, event free survival; OS, overall survival.